Latham & Watkins Represents Neumora Therapeutics in IPO

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company redefining neuroscience drug development, has announced the pricing of its initial public offering of 14,710,000 shares of its common stock at a price to the public of US$17.00 per share. All of the shares are being offered by Neumora. The gross proceeds of the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Neumora, are expected to be approximately US$250 million. In addition, Neumora has granted the underwriters a 30-day option to purchase up to 2,206,500 additional shares of common stock at the initial public offering price, less underwriting discounts and commissions. The shares are expected to begin trading on the Nasdaq Global Select Market on September 15, 2023 under the ticker symbol “NMRA.” The initial public offering is expected to close on September 19, 2023, subject to the satisfaction of customary closing conditions.

Latham & Watkins LLP represents Neumora Therapeutics in the offering with a capital markets team led by Bay Area partner Phillip Stoup and Orange County partner Shayne Kennedy, with Bay area associates Tess Bloom, Natalie Robertson, and Billy Wu. Advice was also provided on regulatory matters by Washington, D.C. partner Elizabeth Richards, Bay Area partner Betty Pang, and Washington, D.C. counsel Chad Jennings; on IP matters by Bay Area partner Christopher Hazuka, with San Diego associate Kristina Funahashi; on tax matters by Bay Area partner Kirt Switzer; and on compensation and benefits matters by Bay Area partner James Metz.